Innovotech Inc. Strengthens Executive Team and Announces New Edmonton Facility Lease

(TheNewswire)

Edmonton, Alberta – February 5, 2026 – TheNewswire - Innovotech Inc. (TSXV: IOT)(“Innovotech” or the “Company”) is pleased to announce theappointments of Jodi McDonald as Chief Operating Officer (“COO”)and Rod Szarka as Chief Commercial Officer (“CCO”) of the Company,each effective February 1, 2026. The Company is also pleased toprovide a corporate update regarding a new facility lease in Edmonton,Alberta.

Appointment of Chief Operating Officer

Ms. McDonald was previously President of Keystone Labs Inc.(“Keystone”), which was recently amalgamated with Innovotech LabsCorporation (“Labs”). Both Keystone and Labs were wholly ownedsubsidiaries of Innovotech Inc., and their amalgamation into a singleentity as Innovotech Labs Corporation was previously announced onJanuary 2, 2026, having been completed on January 1st, 2026.

Ms. McDonald has led Keystone for more than 20 years, building andscaling a regulated laboratory business with a strong focus onquality, client service and team development. She holds a Bachelor ofScience in Medical Laboratory Science from the University of Alberta.

“Over the last two decades, Jodi has built and led a laboratoryorganization that understands how to deliver high quality sciencewhile taking care of people,” said Dr. Craig Milne, CEO ofInnovotech. “She is a proven people leader who knows the realitiesof running complex laboratory operations, meeting regulatoryexpectations, supporting demanding programs and building cultureswhere talented scientists can do their best work. Her experienceintegrating quality, operations and people leadership will be centralas we continue to grow Innovotech as a leading life sciencesCRO.”?quality science while taking care of people,” said Dr.Craig Milne, Chief Executive Officer of Innovotech. “She is a proventeam and people leader who knows the realities of running complexlaboratory operations—meeting regulatory expectations, supportingdemanding programs and building cultures where talented scientists cando their best work. Her experience integrating quality, operations andpeople leadership will be central as we continue to grow Innovotech asa leading life sciences CRO.”

“I am honoured to take on the Chief Operating Officer role atInnovotech,” said Ms. McDonald. “Having worked closely with thisteam for many years, I know the depth of talent across ourlaboratories. My focus will be on empowering our people, strengtheningour operational and quality systems, and ensuring that our clientsexperience the consistency, reliability and responsiveness they needto advance their programs.”

Appointment of Chief Commercial Officer

Innovotech is also pleased to announce the appointment of Rod Szarkaas Chief Commercial Officer. Mr. Szarka was previously Vice Presidentof Marketing and Business Development at Keystone, where he wasresponsible for building client relationships and expanding serviceofferings.  In his new role as CCO of Innovotech, Mr. Szarka willoversee revenue generation across the Company, includingresponsibility for business development, client relationships and thebuildout of a dedicated sales and client service team for allInnovotech business lines.?out of a dedicated sales and clientservice team for all Innovotech business lines.

“Rod has a strong track record of translating technical capabilitiesinto clear value for clients,” added Dr. Milne. “His experiencegrowing Keystone’s client base and his understanding of the needs ofregulated life sciences companies make him the right leader to buildout Innovotech’s commercial engine. With Jodi focused on operationsand Rod focused on growth, we are strengthening the leadership teamneeded to scale our life sciences business.”

“I am excited to step into the Chief Commercial Officer role atInnovotech,” said Mr. Szarka. “Innovotech’s combinedcapabilities in analytical chemistry, microbiology and specializedtesting position us as a valuable partner for life science and medicaldevice clients. My priority will be to deepen relationships withexisting clients, expand our reach to new partners, and build a highperforming commercial team that keeps client needs at the centre ofeverything we do.”?performing commercial team that keeps clientneeds at the centre of everything we do.”

New Edmonton Facility Lease

The Company also announces that the lease for the space currentlyoccupied by the former Keystone segment of Innovotech is expected toend on or about March 31, 2026.  Innovotech has signed a new leasefor premises located at 9407 20 Ave., Edmonton, Alberta, commencingFebruary 1, 2026. The lease has a 14-month term, running to March 31,2027, and includes month-to-month extensions thereafter, providing theCompany with flexibility as it evaluates longer term facility options. “The new space will encompass our analytical chemistry and GMPmicrobiology related work,” said Dr. Milne. “It gives us theflexibility we need as we continue to seek a more permanent solutionfor our growing life sciences businesses and to expand the specializedservices that we offer to drug development and manufacturingclients.”  Innovotech’s offices and antimicrobial contractresearch labs remain at 2011 94 St NW.?month term, running to March31, 2027, and includes month?to?month ?term facilityoptions.?microbiology related work,” said Dr. Milne. “It givesus the flexibility we need as we continue

About Innovotech

Innovotech Inc. is a Canadian boutique contract research organizationspecializing in advanced laboratory services and commercializingproprietary technologies. A leader in biofilm science, the companyprovides expertise in antimicrobial testing, pharmaceutical analysis,and industrial laboratory solutions, supported by innovativemethodologies and products including its widely-usedMBECAssay® kit for high-throughputantimicrobial and antibiotic testing. Innovotech serves clientsacross multiple sectors, delivering customized research and testingservices designed to meet rigorous regulatory and scientific standardssuch as those of the U.S. Food and Drug Administration and HealthCanada through its ISO-certified and GMP-accredited laboratories.Learn more at https://www.innovotech.ca.

Craig Milne, CEO    Innovotech Inc.

+1-604-239-1819 craig.milne@innovotech.ca

This document may containforward-looking statements that are predictive in nature and subjectto risks and uncertainties that cannot be predicted or quantified;consequently, actual results may differ materially from past resultsand those expressed or implied by any forward-looking statements.Factors that could cause or contribute to such risks or uncertaintiesinclude, but are not limited to: the regulatory environment includingthe difficulty of predicting regulatory outcomes; changes in the valueof the Canadian dollar; the Company’s reliance on a small number ofcustomers including government organizations; fluctuations inoperating results; government policies or actions; progress and costof clinical trials; reliance on key strategic relationships;uncertainty related to intellectual property protection and potentialcosts associated with its defense; the Company’s exposure tolawsuits and other matters beyond the control of management. Shouldknown or unknown risks or uncertainties materialize, or shouldmanagement’s assumptions prove inaccurate, actual results could varymaterially from those anticipated. The Company undertakes noobligation to publicly make or update any forward- looking statements,except as required by applicable law.

Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this release.

###

Copyright (c) 2026 TheNewswire - All rights reserved.